Belite Bio (BLTE) News Today $82.81 -0.85 (-1.02%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 13.5%Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 234,000 shares, a drop of 13.5% from the October 15th total of 270,600 shares. Based on an average trading volume of 52,000 shares, the days-to-cover ratio is presently 4.5 days.November 16 at 11:32 AM | marketbeat.comBelite Bio price target raised to $110 from $60 at MaximNovember 16 at 1:40 AM | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim GroupMaxim Group raised their price objective on shares of Belite Bio from $60.00 to $110.00 and gave the company a "buy" rating in a research note on Friday.November 15 at 1:21 PM | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Expected to Rise, HC Wainwright Analyst SaysNovember 15 at 4:15 AM | americanbankingnews.comAnalysts Offer Insights on Healthcare Companies: Belite Bio, Inc. ADR (BLTE), Mereo Biopharma Group Plc (MREO) and Fate Therapeutics (FATE)November 15 at 2:17 AM | markets.businessinsider.comBelite Bio’s Promising Clinical Trials and Strong Financial Position Justify Buy RatingNovember 15 at 2:17 AM | markets.businessinsider.comBelite Bio Advances in Retinal Disease TrialsNovember 13, 2024 | markets.businessinsider.comBelite Bio price target raised to $100 from $60 at H.C. WainwrightNovember 13, 2024 | markets.businessinsider.comBelite Bio, Inc: Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 13, 2024 | finanznachrichten.deInsights into Belite Bio's Upcoming EarningsNovember 13, 2024 | benzinga.comBelite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 13, 2024 | markets.businessinsider.comBelite Bio, Inc. (BLTE) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comBelite Bio, Inc 2024 Q3 - Results - Earnings Call PresentationNovember 12, 2024 | seekingalpha.comBelite Bio (BLTE) Scheduled to Post Earnings on TuesdayBelite Bio (NASDAQ:BLTE) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.November 6, 2024 | marketbeat.comBelite Bio Offers New Warrant Opportunities to InvestorsNovember 5, 2024 | markets.businessinsider.comBelite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial ResultsNovember 5, 2024 | globenewswire.comBelite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Here's What HappenedBelite Bio (NASDAQ:BLTE) Sees Large Volume Increase - Still a Buy?November 4, 2024 | marketbeat.comBelite Bio Announces Exercise of Warrants for US$28.75 Million Gross ProceedsNovember 3, 2024 | globenewswire.comBelite Bio (NASDAQ:BLTE) Reaches New 12-Month High - What's Next?Belite Bio (NASDAQ:BLTE) Hits New 1-Year High - Still a Buy?October 24, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Stock Price Up 4% - Should You Buy?Belite Bio (NASDAQ:BLTE) Stock Price Up 4% - Time to Buy?October 23, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Reaches New 1-Year High - Here's What HappenedBelite Bio (NASDAQ:BLTE) Reaches New 1-Year High - Time to Buy?October 18, 2024 | marketbeat.comBelite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual MeetingOctober 15, 2024 | markets.businessinsider.comBelite Bio to Participate in the Maxim Group 2024 Healthcare Virtual SummitOctober 8, 2024 | finance.yahoo.comBelite Bio (NASDAQ:BLTE) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comBelite Bio (NASDAQ:BLTE) Stock, Short Interest ReportOctober 4, 2024 | benzinga.comBelite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69Belite Bio (NASDAQ:BLTE) Sets New 12-Month High at $50.69October 3, 2024 | marketbeat.comCassava settles SEC charges related to Alzheimer’s candidate for $40MSeptember 28, 2024 | seekingalpha.comArmistice Capital LLC Makes New $6.76 Million Investment in Belite Bio, Inc (NASDAQ:BLTE)Armistice Capital LLC purchased a new position in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 148,000 shares of the company's stock, valued at approxiSeptember 26, 2024 | marketbeat.comHere's Why We're Not At All Concerned With Belite Bio's (NASDAQ:BLTE) Cash Burn SituationSeptember 24, 2024 | finance.yahoo.comShort Interest in Belite Bio, Inc (NASDAQ:BLTE) Declines By 5.1%Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 270,200 shares, a decline of 5.1% from the August 15th total of 284,800 shares. Based on an average daily trading volume, of 44,000 shares, the short-interest ratio is currently 6.1 days.September 18, 2024 | marketbeat.comBelite Bio's (BLTE) "Buy" Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Belite Bio in a report on Thursday.September 12, 2024 | marketbeat.comBelite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt DiseaseSeptember 10, 2024 | stockhouse.comBelite Bio Inc (D01.DU)September 6, 2024 | nz.finance.yahoo.comBelite Bio to Participate in Three Upcoming Investor ConferencesSeptember 3, 2024 | finance.yahoo.comBelite Bio Appoints Hendrik Scholl As Chief Medical OfficerSeptember 2, 2024 | markets.businessinsider.comBelite Bio, Inc (NASDAQ:BLTE) Sees Significant Decrease in Short InterestBelite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 284,800 shares, a drop of 9.6% from the July 31st total of 315,200 shares. Based on an average daily trading volume, of 50,200 shares, the days-to-cover ratio is presently 5.7 days.September 1, 2024 | marketbeat.comBelite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical OfficerSeptember 1, 2024 | globenewswire.comBelite Bio (NASDAQ:BLTE) Sees Unusually-High Trading VolumeBelite Bio (NASDAQ:BLTE) Sees Large Volume IncreaseAugust 30, 2024 | marketbeat.comShort Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7%Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 315,200 shares, an increase of 10.7% from the July 15th total of 284,700 shares. Based on an average daily trading volume, of 53,800 shares, the short-interest ratio is presently 5.9 days.August 17, 2024 | marketbeat.comBelite Bio, Inc.: Strong Buy Rating on Robust Financials and Promising Clinical TrialsAugust 16, 2024 | markets.businessinsider.comBelite Bio (NASDAQ:BLTE) Trading Down 1.8%Belite Bio (NASDAQ:BLTE) Stock Price Down 1.8%August 15, 2024 | marketbeat.comFY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE)Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Belite Bio in a report issued on Tuesday, August 13th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will earn ($1.17) per shAugust 15, 2024 | marketbeat.comQ1 2025 Earnings Forecast for Belite Bio, Inc (NASDAQ:BLTE) Issued By HC WainwrightBelite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.29) per shAugust 14, 2024 | marketbeat.comBuy Rating Affirmed for Belite Bio, Inc. ADR on Strong Clinical Progress and Financial StabilityAugust 14, 2024 | markets.businessinsider.comBuy Rating Affirmed for Belite Bio Amidst Promising Developments for TinlarebantAugust 13, 2024 | markets.businessinsider.comBelite Bio, Inc (BLTE) Q2 2024 Earnings Call TranscriptAugust 13, 2024 | seekingalpha.comHC Wainwright Boosts Belite Bio (NASDAQ:BLTE) Price Target to $60.00HC Wainwright boosted their target price on shares of Belite Bio from $59.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday.August 13, 2024 | marketbeat.comBelite Bio (NASDAQ:BLTE) Rating Reiterated by BenchmarkBenchmark reissued a "buy" rating and set a $57.00 price objective on shares of Belite Bio in a report on Tuesday.August 13, 2024 | marketbeat.comBelite Bio, Inc 2024 Q2 - Results - Earnings Call PresentationAugust 12, 2024 | seekingalpha.comBelite Bio (NASDAQ:BLTE) Shares Gap Down Following Weak EarningsBelite Bio (NASDAQ:BLTE) Shares Gap Down Following Weak EarningsAugust 12, 2024 | marketbeat.com Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address The only candlestick pattern worth a darn (Ad)It’s widely known that 80% of daily market action is driven by Wall Street algorithms… Now, most people think of the algorithms are “bad” When in reality, they are neither good nor bad… They are simply programmed to buy and sell certain stocks over and over again… But here is the thing… They are predictable… They typically buy the same stocks at the same levels over and over again… Follow this link here and enter your email address to sign up… BLTE Media Mentions By Week BLTE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BLTE News Sentiment▼0.700.56▲Average Medical News Sentiment BLTE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BLTE Articles This Week▼182▲BLTE Articles Average Week Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ITCI News ROIV News JAZZ News ASND News MDGL News LEGN News ELAN News VKTX News CYTK News BPMC News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BLTE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts